Experimental Prophylaxis Beneficial for Patients Undergoing HSCT
FRIDAY, June 23, 2023 -- For patients with hematologic cancer undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), graft-versus-host-disease (GVHD)-free, relapse-free survival is more common among those receiving...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Transplants